-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RjgzTdHVdJD5gh0T+H4Msia6ErZAAPPQZttMybl7hRh7DOS8WbLmutNc84xPl6Jt
 EoUGrHwWOkLDx0mZ2U31gQ==

<SEC-DOCUMENT>0001144204-04-005273.txt : 20040422
<SEC-HEADER>0001144204-04-005273.hdr.sgml : 20040422
<ACCEPTANCE-DATETIME>20040422102146
ACCESSION NUMBER:		0001144204-04-005273
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20040422

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-45573
		FILM NUMBER:		04747064

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AXIOM VENTURE ADVISORS INC
		CENTRAL INDEX KEY:			0001280246
		IRS NUMBER:				061392417
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		666 THIRD AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2129353000

	MAIL ADDRESS:	
		STREET 1:		C/O AXIOM VENTURE PARTNERS L P
		STREET 2:		185 ASYLUM ST
		CITY:			HARTFORD
		STATE:			CT
		ZIP:			06103
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>v02841_sc13da.txt
<TEXT>


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13D
                                 (RULE 13D-101)

             INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
            TO RULE 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO
                                  RULE 13D-2(A)

                               (AMENDMENT NO. 3)*


                            ANIKA THERAPEUTICS, INC.
- --------------------------------------------------------------------------------
                                (Name of Issuer)


                     COMMON STOCK, PAR VALUE $0.01 PER SHARE
- --------------------------------------------------------------------------------
                         (Title of Class of Securities)


                                    035255108
                  ---------------------------------------------
                                 (CUSIP Number)


                              Frank J. Marco, Esq.
               Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
                          Connecticut Financial Center
                                157 Church Street
                               New Haven, CT 06510
                                 (203) 777-8200
- --------------------------------------------------------------------------------
            (Name, Address and Telephone Number of Person Authorized
                     to Receive Notices and Communications)


                                 April 12, 2004
                  ---------------------------------------------
             (Date of Event which Requires Filing of this Statement)


If the filing person has previously  filed a statement on Schedule 13G to report
the  acquisition  that is the subject of this  Schedule  13D, and is filing this
schedule  because of Rule  13d-1(e),  13d-1(f) or 13d-1(g),  check the following
box. |_|

NOTE:  Schedules  filed in paper format shall include a signed original and five
copies of the schedule,  including all exhibits.  See ss. 240.13d-7(b) for other
parties to whom copies are to be sent.

*The  remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for  any  subsequent   amendment   containing   information  which  would  alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).

<PAGE>

==================================================
CUSIP NO.  035255108                  13D
==================================================

- --------------------------------------------------------------------------------
1     NAMES OF REPORTING PERSONS
      Axiom Venture Partners L.P. (the "Reporting Person")

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 06-1392421

- --------------------------------------------------------------------------------

2     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                   (a) |_|
                                                                         (b) |_|

- --------------------------------------------------------------------------------

3     SEC USE ONLY

- --------------------------------------------------------------------------------

4     SOURCE OF FUNDS

      N/A

- --------------------------------------------------------------------------------
5     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
      2(d) or 2(e)                                                           |_|

- --------------------------------------------------------------------------------

6     CITIZENSHIP OR PLACE OF ORGANIZATION

              State of Delaware

- --------------------------------------------------------------------------------
       NUMBER OF         7      SOLE VOTING POWER
         SHARES
      BENEFICIALLY              65,926
        OWNED BY        --------------------------------------------------------
          EACH           8      SHARED VOTING POWER
       REPORTING
         PERSON                 0
          WITH
                        --------------------------------------------------------
                         9      SOLE DISPOSITIVE POWER

                                65,926

                        --------------------------------------------------------
                        10      SHARED DISPOSITIVE POWER

                                0

- --------------------------------------------------------------------------------
11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

      65,926

- --------------------------------------------------------------------------------
12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  |_|


- --------------------------------------------------------------------------------
13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      .006%

- --------------------------------------------------------------------------------
14    TYPE OF REPORTING PERSON

      PN

- --------------------------------------------------------------------------------

                                Page 2 of 4 pages
<PAGE>


Item 1.           Security and Issuer

      This  Amendment  No. 3 to Schedule  13D relates to the common  stock,  par
value $0.01 per share (the  "Common  Stock"),  of Anika  Therapeutics,  Inc.,  a
Massachusetts corporation, whose principal executive officers are located at 160
New Boston Street,  Woburn,  Massachusetts  01801.  The Reporting  Person hereby
amends its  statement  on Schedule 13D relating to the shares of Common Stock as
set forth below.

Item 5.           Interest in Securities of the Issuer

      Items 5 of the statement on Schedule 13D filed by the Reporting  Person on
December 1, 1997 is hereby amended and restated to read as follows:

(a) As of the date hereof,  the Reporting Person is deemed to beneficially  own,
in the aggregate,  65,926 shares of Common Stock  underlying  stock options that
are exercisable within 60 days of the date hereof.

(b) Not applicable.

(c) The following table sets forth all  transactions  with respect to the shares
of Common Stock  effected since the most recent filing on Schedule 13D by any of
the Reporting Persons.


                                                         NUMBER OF SHARES
NAME                                         DATE          DISTRIBUTED
- ----                                         ----          -----------

Axiom Venture Partners, L.P.                4/12/04           845,710


(d) Not applicable.

(e) On April 12, 2004 the Reporting Person made a distribution of 845,710 shares
of Common Stock (which amount  included 3,020 shares of Common Stock received as
a result of the issuance of  dividends)  to its general  partner and its limited
partners. As of April 12, 2004, the Reporting Person ceased to be the beneficial
owner of more than five percent of the Common Stock.


                                Page 3 of 4 pages
<PAGE>


                                    SIGNATURE


      After  reasonable  inquiry and to the best of my knowledge  and belief,  I
certify that the information  set forth in this statement is true,  complete and
correct.


Date:    April 21, 2004

AXIOM VENTURE PARTNERS L.P.

By:      /s/ AXIOM VENTURE ASSOCIATES L.P.
         Axiom Venture Associates L.P.
         Its General Partner

         By:      /s/ Samuel McKay
                  Samuel McKay



                                Page 4 of 4 pages


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
